Covalab and partners CimCure, Amsterdam UMC and the University of Zurich join forces on this project with total public and private fundings of €2.24M, including the Eurostars grant, to develop novel immunotherapy combining CAR-T cells and CimCure’s iBoost vaccines to treat glioblastoma
Bron, France, September 20, 2022 – Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and antibodies for diagnostics and therapeutics, today announces that together with CimCure, a Dutch biotech company focusing on the development of a novel vaccine-based immunotherapy, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), they have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total budget of €2.24M ($2.28M,) including investments from the partners, the project aims to develop a new treatment against glioblastoma. CimCure B.V. is the lead coordinator of the project.
